A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Metastatic Solid Tumor(s)|Prostate Cancer|Esophageal Cancer|Triple Negative Breast Cancer (TNBC)|Squamous Cell Carcinoma of Head and Neck (SCCHN)|Non-small Cell Lung Cancer (NSCLC)|Bladder Cancer|Uterine Cancer
Interventions: BIOLOGICAL: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Sponsor: Genmab
Collaborators: AbbVie